SAN DIEGO, Dec. 26, 2025 (GLOBE NEWSWIRE) -- As the post-holiday period brings renewed interest in weight management options, individuals researching GLP-1 telehealth platforms are seeking answers to fundamental questions: Which providers are legitimate? What do the medications actually cost? And how does the process work? SynergyRx, a telehealth platform connecting patients with licensed medical…
CIUDAD DE MÉXICO, March 05, 2026 (GLOBE NEWSWIRE) -- Mantenerse en el estatus de cumplimiento del GAFI es, para México, un objetivo tan exigente como estratégico. Las sanciones de FinCEN del Departamento del Tesoro de EE.UU. contra CIBanco, Intercam Banco y Vector Casa de Bolsa en junio de 2025, por presunta facilitación de lavado de…
Silicon Valley, CA, March 05, 2026 (GLOBE NEWSWIRE) -- Resilinc, the leading provider of agentic AI-driven supply chain risk and compliance intelligence, today announced it has architected its platform on the Databricks Platform to power large-scale, multi-tier supply chain intelligence for manufacturing and regulated industries.
Dublin, March 05, 2026 (GLOBE NEWSWIRE) -- The "Cooling Fabrics - Company Evaluation Report, 2025" report has been added to ResearchAndMarkets.com's offering. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and industry trends. The 360 Quadrants evaluated over 107 companies, of which the Top 16 Cooling Fabrics Companies were…
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of…
